| Literature DB >> 34080711 |
Xinhang Wang1, Lulu Chen1, Jinbao Huang1, Jianguang Pan1, Mingxiang Huang2, Lizhou Chen1.
Abstract
BACKGROUND: To explore the clinical manifestation, imaging examination, and serology of patients with novel coronavirus pneumonia (COVID-19) between China and overseas.Entities:
Keywords: China; clinical characteristics; novel coronavirus pneumonia; overseas
Mesh:
Substances:
Year: 2021 PMID: 34080711 PMCID: PMC8209900 DOI: 10.1002/jcla.23811
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 3.124
General clinical characteristics between the two groups
| Clinical characteristics |
Domestic group ( |
Overseas group ( | t/z/χ2 |
|
|---|---|---|---|---|
| Basic data | ||||
| Male | 34/71 (47.9%) | 8/19 (42.1%) | 0.201 | 0.654 |
| Age (years) | 46.7 ± 17.6 | 46.1 ± 16.7 | 0.136 | 0.892 |
| BMI | 23.63 ± 3.2 | 22.2 ± 2.7 | 1.659 | 0.101 |
| Basic diseases | ||||
| None | 33/71 (46.5%) | 7/19 (36.8%) | 0.564 | 0.604 |
| Respiratory diseases | 8/71 (11.3%) | 4/19 (21.1%) | 1.242 | 0.271 |
| Diabetes mellitus | 5/71 (7.0%) | 3/19 (15.8%) | 1.416 | 0.234 |
| Hypertension | 13/71 (18.3%) | 5/19 (26.3%) | 0.600 | 0.438 |
| Heart disease | 2/71 (2.8%) | 0/19 (0%) | — | 1.000 |
| Tumors | 7/71 (9.9%) | 4/19 (21.1%) | 1.751 | 0.186 |
| Mental diseases | 3/71 (4.2%) | 0/19 (0%) | — | 1.000 |
| Hepatitis B virus infection | 10/71 (14.1%) | 2/19 (10.5%) | 0.164 | 0.685 |
| Kidney disease | 6/71 (8.5%) | 3/19 (15.8%) | 0.897 | 0.344 |
| Nervous system | 5/71 (7.0%) | 1/19 (5.3%) | 0.076 | 0.782 |
The clinical manifestations in the two groups
| Clinical manifestations |
Domestic group ( |
Overseas group ( | t/z/χ2 |
|
|---|---|---|---|---|
| Cough | 44/71 (62%) | 6/19 (31.6%) | 5.607 | 0.018 |
| Expectoration | 34/71 (47.9%) | 6/19 (31.6%) | 1.615 | 0.204 |
| Hemoptysis | 2/71 (2.8%) | 0/19 (0%) | — | 1.000 |
| Dyspnea | 16/71 (22.5%) | 0/19 (0%) | 0.019 | |
| Chest tightness | 7/71 (9.9%) | 2/19 (10.5%) | 0.007 | 0.931 |
| Fever | 59/71 (83.1%) | 9/19 (47.4%) | 10.361 | 0.001 |
| Dizzy | 6/71 (8.5%) | 1/19 (5.3%) | 0.212 | 0.645 |
| Weakness | 15/71 (21.1%) | 2/19 (10.5%) | 1.099 | 0.294 |
| Anorexia | 20/71 (28.2%) | 9/19 (47.4%) | 2.53 | 0.112 |
| Loss of taste and smell | 0/71 (0) | 2/19 (10.5%) | ||
| Nausea | 0/71 (0) | 1/19 (5.3%) | — | 0.211 |
| Abdominal pain | 1/71 (1.4%) | 0/19 (0%) | — | 1.000 |
| The whole body aches | 4/71 (5.6%) | 1/19 (5.3%) | 0.004 | 0.950 |
| Nasal congestion | 2/71 (2.8%) | 0/19 (0%) | — | 0.226 |
| Runny nose | 3/71 (4.2%) | 0/19 (0%) | — | 1.000 |
| Fear of cold and shivering | 9/71 (12.7%) | 4/19 (21.1%) | 0.851 | 0.356 |
| Complicated with respiratory symptoms | 3/71 (4.2%) | 3/19 (15.5%) | 3.221 | 0.073 |
| Proportion of severe and critical illness | 66/71 (93.1%) | 12/19 (63.2%) | 11.519 | 0.001 |
The laboratory and imaging examinations in the two groups
| Clinical manifestations |
Domestic group ( |
Overseas group ( | t/z |
|
|---|---|---|---|---|
| Blood gas analysis | ||||
| PH | 7.40 ± 0.036 | 7.40 ± 0.032 | −0.56 | 0.577 |
| PO2 | 106.61 ± 28.51 | 99.21 ± 18.82 | 1.117 | 0.267 |
| PCO2 | 34.33 ± 4.29 | 35.87 ± 4.61 | −1.419 | 0.159 |
| PO2/FiO2 | 442.70 ± 144.70 | 456.38 ± 93.90 | −0.512 | 0.611 |
| SO2 | 97.8 (97.1–98.5) | 97.7 (96.3–98.4) | −0.883 | 0.377 |
| Routine blood test | ||||
| WBC | 5.86 ± 2.36 | 4.58 ± 1.45 | 2.366 | 0.02 |
| NEUT | 4.02 ± 1.71 | 2.88 ± 1.01 | 3.799 | 0.000 |
| NEUT% | 0.68 ± 0.12 | 0.62 ± 0.10 | 1.292 | 0.057 |
| LY% | 0.23 ± 0.11 | 0.27 ± 0.08 | −1.11 | 0.243 |
| LY | 1.13 (0.81–1.62) | 1.11 (0.76–1.69) | −0.018 | 0.985 |
| Monocyte | 0.39 ± 0.19 | 0.38 ± 0.13 | 0.167 | 0.868 |
| HGB | 134.64 ± 21.50 | 133.52 ± 13.59 | 0.224 | 0.823 |
| PLT | 209.06 ± 65.47 | 182.24 ± 63.32 | 0.965 | 0.1 |
| ESR | 37.45 ± 26.95 | 20.52 ± 14.09 | 3.815 | 0.000 |
| CRP | 9.57 (3.94–27.98) | 4.04 (0.84–12.55) | −2.288 | 0.022 |
| PCT | 0.04 (0.02–0.07) | 0.027 (0.02–0.41) | −1.83 | 0.067 |
| D‐Dimer | 0.051 (0.019–0.199) | 0.019 (0.019–0.13) | −0.964 | 0.335 |
| GLB | 28.5 (26.5–30.6) | 26.1 (25.3–29.5) | −1.967 | 0.049 |
| BUN | 3.9 (3.0–4.5) | 3.5 (2.4–3.9) | −1.673 | 0.094 |
| CREA | 61.7 (52–75.5) | 53 (44.5–66.5) | −1.668 | 0.095 |
| CK | 60.5 (38.2–130) | 75.3 (58.2–105) | −0.763 | 0.446 |
| CK‐MB | 0.88 (0.53–1.51) | 1.05 (0.71–1.55) | −0.836 | 0.403 |
| TNT | 5.03 (3.52–7.41) | 5.72 (3.8–9.37) | −0.718 | 0.473 |
| MYO | 23.11 (21–49.48) | 21 (21–36.51) | −1.317 | 0.188 |
| Mg | 0.9 (0.8–0.9) | 0.8 (0.8–0.9) | −1.905 | 0.057 |
| Decreased oxygenation | 11/71 (15.5%) | 1/19 (5.3%) | 1.357 | 0.244 |
| Leukopenia | 9/71 (12.7%) | 6/19 (31.6%) | 3.856 | 0.05 |
| Lymphocytopenia | 33/71 (46.5%) | 10/19 (52.5%) | 0.227 | 0.797 |
| CRP | 34/71 (47.9%) | 7/19 (36.8%) | 0.391 | |
| ESR | 49/71 (69%) | 9/19 (47.4%) | 0.08 | |
| Increased LDH | 63/71 (88.7%) | 14/19 (73.7%) | 2.747 | 0.097 |
| Imaging features | ||||
| Bilateral pneumonia | 65/71 (91.5) | 15/19 (78.9%) | 2.41 | 0.121 |
| Multiple patchy shadows and ground glass shadows | 47/71 (66.2%) | 12/19 (63.2) | 0.061 | 0.804 |
| Peripheral pneumonia | 42/71 (59.2%) | 10/19 (52.6%) | 0.261 | 0.613 |
| Interstitial lesions | 42/71 (59.2%) | 12/19 (63.2%) | 0.100 | 0.752 |
| Ground glass opacity | 47/71 (66.2%) | 13/19 (68.4%) | 0.033 | 0.855 |
| Multiple plaques | 64/71 (90.1%) | 17/19 (89.5%) | 0.007 | 0.931 |
| Multiple exudates | 59/71 (83.1%) | 17/19 (89.5%) | 0.464 | 0.496 |
| Nodular shadow | 43/71 (60.6%) | 12/19 (63.2%) | 0.042 | 0.837 |
| Pleural effusion | 6/71 (8.5%) | 1/19 (5.3%) | 0.212 | 0.645 |
Abbreviation: ESR, erythrocyte sedimentation rate; WBC, White blood cell; NEUT, Neutrophils; LY, lymphocyte; HGB, Hemoglobin; PLT, platelet; CRP, C‐reactive protein; PCT, Procalcitonin; GLB, Globulin; BLUN, Blood urea nitrogen; CREA, creatinine; CK, creatine kinase; CK‐MB, creatine kinase isoenzyme; TNT, Troponin T; MYO, myoglobin; CRP, C‐reactive protein; LDH, lactate dehydrogenase.
Clinical treatment and prognosis in the two groups
| Clinical treatment and prognosis |
Domestic group ( |
Overseas group ( | t/z/χ2 |
|
|---|---|---|---|---|
| Treatment | ||||
| Use of antibiotics | 25/71 (35.2%) | 6/19 (31.6%) | 0.088 | 0.522 |
| Use of hormones | 10/71 (14.1%) | 1/19 (5.3%) | 1.087 | 0.2297 |
| Oxygen supply | 34/71 (47.9%) | 7/19 (36.8%) | 0.737 | 0.397 |
| Prognosis | ||||
| Time of turning negative | 12 ± 5 | 18 ± 6 | −3.946 | 0.000 |
| Antipyretic time | 3 (0–8) | 7.5 (3–11) | −1.616 | 0.106 |
FIGURE 1Correlation between clinical symptoms, oxygenation, and prognosis in the two groups